Showing results (111-120 of 133) with videos related to

Sort By:
Pageof 14
Molecular Cell|January 28, 2014
Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitorsMehdi Mollapour, Dimitra Bourboulia, Kristin Beebe, et al.
Expert Opinion on Investigational Drugs|December 10, 2016
RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trialsBryan Oronsky, Ramasamy Paulmurugan, Kira Foygel, et al.
Neuro-Oncology|October 31, 2019
Metabolic reprogramming associated with aggressiveness occurs in the G-CIMP-high molecular subtypes of IDH1mut lower grade gliomasVictor Ruiz-Rodado, Tathiane M Malta, Tomohiro Seki, et al.
Clinical Genitourinary Cancer|June 23, 2016
A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial CarcinomaAndrea B Apolo, Fatima H Karzai, Jane B Trepel, et al.
Cell Reports|January 26, 2016
Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 InhibitorsMark R Woodford, Andrew W Truman, Diana M Dunn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2017
Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid TumorsAnish Thomas, Christophe E Redon, Linda Sciuto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2021
E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research GroupRoisin M Connolly, Fengmin Zhao, Kathy D Miller, et al.
Pageof 14